Medherant said today that it successfully finished two Phase I studies with its ibuprofen transdermal drug-delivery patch.
According to the UK-based company, the Tepi patch was well tolerated by the participants of a skin irritation study.
The company also touted results from a second study, which compared blood concentrations of ibuprofen following repeated application of the Tepi patch versus a single oral dose of ibuprofen. Medherant reported that blood levels of ibuprofen were significantly lower following application of the patch, indicating that the patch was successful as a means of localized drug delivery.
Medherant also noted that it is looking for financial support in a Series A round to support a Phase III study of the ibuprofen patch.
“These positive Phase I results signify a major milestone in the ongoing development of our Tepi Patch drug delivery technology and demonstrate that our novel adhesive can be used safely,” CEO Nigel Davis said in prepared remarks. “The successful completion of these trials is a testament to our team’s hard work and dedication. We look forward to taking the Ibuprofen Tepi Patch into Phase III clinical testing.”